MADISON, Wis. / Feb 01, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Fourth quarter 2023 webcast & conference call details
Date: | Wednesday, February 21, 2024 |
Time: | 5 p.m. ET |
Webcast: | The live webcast can be accessed at www.exactsciences.com |
Telephone: | Domestic callers, dial 888-330-2384 |
International callers, dial +1 240-789-2701 | |
| Access code for both domestic and international callers: 4437608 |
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
| Last Trade: | US$61.41 |
| Daily Change: | -1.94 -3.06 |
| Daily Volume: | 1,933,788 |
| Market Cap: | US$11.290B |
April 04, 2024 March 28, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
